Skip to main content

Bruker Offers Common Stock; Hopes to Raise $12.6M

NEW YORK, April 23 (GenomeWeb News) - Bruker BioSciences hopes to raise $12.6 million in net proceeds from a public offering of 3 million shares of its common stock, the company said today.

 

The offering coincides with the sale of 12 million shares by four stockholders related to CEO Frank Laukien to the public, which is expected to generate $50.5 million in net proceeds.

 

The stock will be priced at $4.50 per share.

 

Bruker said it plans to use the proceeds for general corporate purposes, potential acquisitions, and possibly for the repayment of debt.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.